NOTIFICATION TO STOCK EXCHANGE
COMPANY STATEMENT
“The U.S. Food and Drug Administration (USFDA) concluded a GMP inspection of our API facility (Site 5), located at Visakhapatnam, Andhra Pradesh, on June 21, 2024. Four observations were cited at the end of the Inspection, which we will be addressing within the stipulated time.
Biocon stands committed to Quality, Safety & Efficacy of the products manufactured.”
You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.
Download Company Statement